An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Axonics Ranked No. 2 on the Financial Times 2023 List of the Fastest Growing Companies in the Americas
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Axonics, Inc. (NASDAQ: AXNX) has achieved a notable milestone by ranking No. 2 on the Financial Times list of the fastest growing companies in the Americas for 2023, following a No. 1 ranking in 2022. The company's revenue surged from $707,000 in 2018 to $180.3 million in 2021, reflecting a remarkable compound annual growth rate of 534% over this period. CEO Raymond W. Cohen highlighted this recognition as a testament to employee dedication and a commitment to innovation, aiming to raise awareness of bladder and bowel dysfunction treatments.
Positive
Ranked No. 2 in Financial Times 2023 list of fastest growing companies in the Americas.
Achieved a compound annual growth rate of 534% from 2018 to 2021.
Negative
None.
IRVINE, Calif.--(BUSINESS WIRE)--
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 2 on the Financial Times2023 list of the fastest growing companies in the Americas. This follows the company’s No. 1 ranking on the 2022 list.
Companies were ranked based on the compound annual growth rate of their revenue from 2018 to 2021. Axonics reported $180.3 million of revenue in fiscal year 2021 compared to $707,000 in fiscal year 2018, representing a compound annual growth rate of 534%.
“Axonics is proud to once again be recognized as one of the fastest growing companies in the Americas,” said Raymond W. Cohen, chief executive officer. “The strong growth of Axonics is a testament to the dedication of our employees and a commitment to continuous innovation. We have built a company that values and rewards quality, integrity, teamwork and first-class customer support. We are working diligently to increase public awareness that urinary incontinence is not a normal part of aging and that Axonics has best-in-class therapies proven to significantly improve the quality of life for adults with bladder and bowel dysfunction.”
About Axonics
Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500.
Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.
